본문으로 건너뛰기
← 뒤로

Timing and clinical significance of chemotherapy in patients with resected gastric adenocarcinoma: a population-based cohort study.

코호트 1/5 보강
The oncologist 📖 저널 OA 97.7% 2022: 2/2 OA 2023: 2/2 OA 2024: 15/15 OA 2025: 88/89 OA 2026: 105/109 OA 2022~2026 2025 Vol.30(7)
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 3/4)

유사 논문
P · Population 대상 환자/모집단
4914 patients, 38.
I · Intervention 중재 / 시술
gastrectomy were extracted from Surveillance, Epidemiology, and End Results database
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
However, older individuals and those with well-differentiated tumors could be considered exempt from further AC after receiving NAC and gastrectomy. Further research is needed to validate these findings and optimize GC management.

Zhang D, Yang Q, Ji C, Zhang X, Song X, Nan Z

📝 환자 설명용 한 줄

[BACKGROUND] This study was to assess the impact of chemotherapy sequence on the prognosis of patients with gastric cancer (GC) undergoing gastrectomy and identify optimal chemotherapy timing along wi

이 논문을 인용하기

↓ .bib ↓ .ris
APA Zhang D, Yang Q, et al. (2025). Timing and clinical significance of chemotherapy in patients with resected gastric adenocarcinoma: a population-based cohort study.. The oncologist, 30(7). https://doi.org/10.1093/oncolo/oyaf179
MLA Zhang D, et al.. "Timing and clinical significance of chemotherapy in patients with resected gastric adenocarcinoma: a population-based cohort study.." The oncologist, vol. 30, no. 7, 2025.
PMID 40592733 ↗

Abstract

[BACKGROUND] This study was to assess the impact of chemotherapy sequence on the prognosis of patients with gastric cancer (GC) undergoing gastrectomy and identify optimal chemotherapy timing along with potential candidates.

[PATIENTS AND METHODS] Data on patients who underwent gastrectomy were extracted from Surveillance, Epidemiology, and End Results database. Prognostic factors for overall survival (OS) were assessed using Kaplan-Meier and Cox regression analyses. Treatment strategies were categorized into neoadjuvant chemotherapy (NAC), adjuvant chemotherapy (AC), and perioperative chemotherapy (PC), with subsequent analyses of clinical outcomes. Stable inverse probability of treatment weighting (sIPTW) and subgroup analyses were conducted to evaluate the significance of chemotherapy timing.

[RESULTS] Among 4914 patients, 38.4% received NAC, 45% received AC, and 16.6% received PC. The 5-year OS rates for the entire cohort were 41.2%. Although no significant differences were observed between NAC and AC, PC exhibited a substantial improvement in OS compared to both. Multivariate analysis highlighted chemotherapy timing as a prognostic factor for OS. Even after sIPTW, PC still demonstrated significantly longer OS compared to NAC and AC, and this trend persisted across almost all subgroups. Even after patients underwent NAC and gastrectomy, AC remained essential. Notably, potential candidates exempt from AC were identified, including patients aged ≥65 years and those with tumor grades I-II.

[CONCLUSIONS] Chemotherapy timing was an independent prognostic factor for resected GC. PC presented as a promising strategy, displaying superior OS compared to both NAC and AC. However, older individuals and those with well-differentiated tumors could be considered exempt from further AC after receiving NAC and gastrectomy. Further research is needed to validate these findings and optimize GC management.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

… 외 1개

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기